Eli Lilly's Zepbound shows promise for treating adolescent obesity

theglobeandmail.com [$] —

Eli Lilly reported strong third-quarter earnings, driven by its weight-loss drug Zepbound, and new clinical trial results suggest a significant growth opportunity in treating adolescents with obesity. The company's study in patients aged 12 to 17 showed Zepbound led to an average weight loss of about 40 pounds over 72 weeks, compared to a 5-pound gain for placebo, with improvements in cholesterol and quality of life. This could support a label expansion for younger patients. With over five million U.S. adolescents potentially affected by obesity, this market could generate an additional $6.5 billion in annual revenue for Eli Lilly, though it faces competition from Novo Nordisk's Wegovy and potential pricing pressures.


With a significance score of 3.7, this news ranks in the top 5.6% of today's 29660 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: